| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and InformationWe have performed integrative analyses of breast cancer tumors, including whole exome sequencing of tumor & normal pairs, whole transcriptome sequencing, and single-cell/nucleus RNA sequencing, to determine molecular correlates of response to novel and immune therapies. We have focused on dissecting the role of anticancer immunity in response to these therapies and understanding biological mechanisms underlying therapeutic resistance. The goal of this work is to advance a precision medicine approach to breast cancer treatment by identifying molecular biomarkers to improve therapy selection and novel therapeutic targets to overcome resistance.
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
- Study Design:
- Case Set
- Study Type:
- Case Set
- Total number of consented subjects: 58
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
-
- Sequence Read Archive
- BioSample
- Clinical Trials
- Study Inclusion/Exclusion Criteria
Inclusion: Patients, who had tumor samples available for genomic sequencing, are enrolled in various trials.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Breast Neoplasms
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Eliezer M. Van Allen, MD. Dana-Farber Cancer Institute, Boston, MA, USA.
-
Funding Sources
- R37 CA222574. National Institutes of Health, Bethesda, MD, USA.
- R01 CA227388. National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator